Saturday, October 31, 2026

Redfin Stock Soars 17% Thursday: Market Outperformance

ViaNews Editorial Team

December 15, 2023

Redfin Stock Soars 17% Thursday: Market Outperformance

(VIANEWS) - Redfin Shares soar 17.222% on NASDAQ, Steadily Extending Recent Uptrend.

About Redfin

Redfin Corporation is a premier residential real estate brokerage firm in both the U.S. and Canada, operating an online real estate marketplace to connect buyers and sellers, title settlement services, mortgage origination services and loan origination and sale. Established in 2002 and based out of Seattle Washington since then, Redfin was previously known as Appliance Computing Inc before changing names in May 2006.

Yearly Analysis

Redfin's stock is currently trading at EUR9.87, significantly below its 52-week high of EUR17.68 but above its low of EUR3.74 from just a year ago. This indicates a significant loss in value. Redfin's sales growth this year is projected to be negative 52.6%; this represents an alarming decline; however, next year is anticipated to experience lower negative 2.6% growth rates; which may signal that performance should improve within the company over the course of 2019. Redfin's EBITDA currently stands at 0.88, indicating its earnings before interest, taxes, depreciation and amortization (EBITDA) is positive but relatively low - potentially signalling to investors that Redfin isn't producing sufficient profitability. Redfin's stock currently offers mixed signals. Although its current stock price is significantly below its 52-week high, negative sales growth this year is cause for alarm; however, expected improvements next year could provide investors with hope of improvement in growth rates. Positive EBITDA values also provide some evidence of profitability though their low value may cause some concern among investors.

Technical Analysis

Redfin Corporation (RDFN) is an American technology-enabled real estate brokerage company which provides a platform for buying and selling homes. As of 14 March 2023, its stock was trading around EUR11.85 - far higher than its 50-day moving average of EUR6.17 and 200-day moving average of EUR9.04; this indicates a bullish trend. Redfin's trading volume today was reported at 121,598,110 - 167.23% higher than its 50-day average volume of 4,550,210. This could indicate increased interest in Redfin, potentially driving its share price upwards. Redfin's intraday variation average has been negative 1.13% over the last week, month and quarter; its highest amplitude of average volatility for those timeframes was 3.53% in each of those time periods; these findings show that its price has been relatively steady over recent months but has experienced slight fluctuations during these time periods. Redfin's stock has recently reached overbought levels according to the stochastic oscillator - a widely used technical indicator that compares its closing price against its price range over an extended period - signalling that its stock may have appreciated too quickly and may soon experience some form of pullback or correction. This may mean it has seen too rapid of an ascent. Redfin's stock price appears to be in an overall bullish trend; however, investors should keep an eye out for potential pullback or correction due to overbought conditions. Furthermore, an increase in trading volume could signify growing investor enthusiasm for Redfin stock and drive its price upward further.

Quarter Analysis

Redfin's current financial performance data indicates a negative sales growth of 54% for this quarter and negative 32.5% for next quarter - suggesting the company is experiencing a revenue decrease that should cause concern to investors. Redfin has provided growth estimates for both the current quarter and next quarter that show strong expected increases of 79.8% and 12.7%, which suggests that they expect significant rebound in growth over time, something investors may take as good sign. Even though Redfin's year-on-year quarterly revenue growth has decreased by 12% year-to-date, its total twelve trailing month revenue still sits at an impressive $2.17B mark; this indicates a substantial revenue base that may provide stability and support for future expansion. Overall, investors should approach Redfin with caution when considering an investment decision. Though Redfin's negative sales growth is cause for alarm, its projected quarterly growth estimates do suggest there could be room for recovery in performance in coming quarters. Investors should continue monitoring Redfin's financial performance and remain up-to-date with any relevant industry trends or developments that might impact it.

Equity Analysis

Redfin's trailing twelve months EPS stands at EUR-1.84, indicating a loss for the company during 2017. Investors should bear in mind that EPS alone does not adequately measure financial performance and should instead evaluate other factors like revenue growth, industry trends and management strategy prior to making investment decisions. Redfin's return on equity (ROE) stands at -209.25% over its trailing twelve month period, signaling to investors that losses exceeded shareholder equity, signalling potential red flags for potential investment decisions. A negative ROE suggests that Redfin may not effectively utilize their shareholder equity to generate profits and produce returns for shareholders. Overall, investors should exercise extreme caution when investing in Redfin given its negative EPS and ROE. Before making their decision, further research and analysis should be conducted, including reviewing its financial statements and industry trends.

More news about Redfin (RDFN).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com